Dr Paul Norwood, MD - University of California at San Francisco - Associate Clinical Professor of Medicine at UC San Francisco

Dr Paul Norwood

MD

University of California at San Francisco

Associate Clinical Professor of Medicine at UC San Francisco

Fresno, CA | United States

Main Specialties: Endocrinology Diabetes & Metabolism, Internal Medicine

Additional Specialties: Diabetes, cholesterol, hypertension,


Top Author

Dr Paul Norwood, MD - University of California at San Francisco - Associate Clinical Professor of Medicine at UC San Francisco

Dr Paul Norwood

MD

Introduction

I have wanted to be a medical doctor since I was 7 years old. I love my job and I love my patients. I will do anything for thim.

Primary Affiliation: University of California at San Francisco - Fresno, CA , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr Paul Norwood’s Resume / CV

Education

Jul 1993
University of California at San Francisco
Associate Clinical Professor of Medicine at UC San Francisco
Jul 1986
University of California at Davis
Fellowship in Endocrinology
Jul 1984
University of California Irvine Long Beach Veterans Hosp.
Internship and Internal Medicine Residency
Jul 1980
Loma Linda University Loma Linda California
Medical Degree
Jul 1975
University of California at Santa Barbara
Bachelors in Biology
Jul 1975
University of California at Santa Barbara
Bachelors in Biology

Experience

Jul 2007
Fellow of the American Association of Endocrinologists
Jul 2007
Fellow of the American Association of Endocrinologists
Jul 1993
Fellow of American College of Physicians

Publications

15Publications

331Reads

463Profile Views

256PubMed Central Citations

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

N Engl J Med. 1997 Jan 2;336(1):1-7.

New England Journal

BACKGROUND: Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat this disorder. METHODS: Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. The men were first tested in the clinic with up to four doses of the drug (125, 250, 500, and 1000 microg); those who had sufficient responses were randomly assigned to treatment with either the effective dose of alprostadil or placebo for three months at home. RESULTS: During in-clinic testing, 996 men (65.9 percent) had erections sufficient for intercourse. Of these men, 961 reported the results of at least one home treatment; 299 of the 461 treated with alprostadil (64.9 percent) had intercourse successfully at least once, as compared with 93 of the 500 who received placebo (18.6 percent, P<0.001). On average, 7 of 10 alprostadil administrations were followed by intercourse in men responsive to treatment. The efficacy of alprostadil was similar regardless of age or the cause of erectile dysfunction, including vascular disease, diabetes, surgery, and trauma (P<0.001 for all comparisons with placebo). The most common side effect was mild penile pain, which occurred after 10.8 percent of alprostadil treatments, but the pain rarely resulted in refusal to continue in the study. Hypotension occurred in the clinic in 3.3 percent of men receiving alprostadil. Hypotension-related symptoms were uncommon at home. No men had priapism or penile fibrosis. CONCLUSIONS: In men with erectile dysfunction, transurethral alprostadil therapy resulted in erections in the clinic and in intercourse at home.

View Article
August 2018
19 Reads

long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population

J Am Geriatr Soc. 2013 Mar;61(3):478.

J Am Geriatr Soc.

Abstract OBJECTIVES: To investigate the efficacy of once-daily oral oseltamivir for 6 weeks (Tamiflu) in prophylaxis against laboratory-confirmed clinical influenza in frail older subjects living in homes for seniors and to determine the safety and tolerability of long-term oseltamivir. DESIGN: Double-blind, placebo-controlled, parallel-group, randomized, multicenter study. SETTING: Thirty-one residential homes for seniors across United States and Europe. PARTICIPANTS: Five hundred forty-eight frail older occupants (mean age 81 years, >80% vaccinated). INTERVENTION: Prophylaxis with oseltamivir 75 mg or placebo once daily for 6 weeks, beginning when influenza was detected locally. MEASUREMENTS: The primary efficacy endpoint was laboratory-confirmed clinical influenza. RESULTS: Oseltamivir administration resulted in a 92% reduction in the incidence of laboratory-confirmed clinical influenza compared with placebo (placebo 12/272 (4.4%), oseltamivir 1/276 (0.4%); P = .002). Of subjects vaccinated against influenza, oseltamivir was 91% effective in preventing laboratory-confirmed clinical influenza (placebo 11/218 (5.0%), oseltamivir 1/222 (0.5%); P = .003). Oseltamivir use was associated with a significant reduction in the incidence of secondary complications (placebo 7/272 (2.6%), oseltamivir 1/276 (0.4%); P = .037). Although nearly all subjects were taking concomitant medication both before and during the study, oseltamivir was well tolerated. A similar incidence of adverse events, including gastrointestinal effects, occurred in both groups. There was no suppression of antibody response in oseltamivir recipients. CONCLUSION: Oral oseltamivir 75 mg once daily for 6 weeks effectively prevented clinical influenza in vaccinated frail older subjects using significant concomitant medications in a residential care setting. The treatment was well tolerated and provided additional protection to that afforded by vaccination.

View Article
August 2018
12 Reads

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

J Clin Endocrinol Metab 2018 06;103(6):2291-2301

University of California at San Francisco, Fresno, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-00070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991220PMC
June 2018
26 Reads
3 Citations
6.210 Impact Factor

Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.

J Sex Med 2014 Mar 28;11(3):857-64. Epub 2013 Nov 28.

Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17436095153070
Publisher Site
http://dx.doi.org/10.1111/jsm.12411DOI Listing
March 2014
23 Reads
3.151 Impact Factor

A novel testosterone 2% gel for the treatment of hypogonadal males.

J Androl 2012 Jul-Aug;33(4):601-7. Epub 2011 Oct 6.

Johns Hopkins University, 1830 Monument St, Suite 328, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.2164/jandrol.111.014308
Publisher Site
http://dx.doi.org/10.2164/jandrol.111.014308DOI Listing
November 2012
17 Reads
4 Citations
2.473 Impact Factor

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Clin Ther 2012 Oct 29;34(10):2082-90. Epub 2012 Sep 29.

University of California at San Francisco, Fresno, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2012.09.007DOI Listing
October 2012
15 Reads
8 Citations
2.731 Impact Factor

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

Diabetes Care 2009 Sep 15;32(9):1656-62. Epub 2009 Jun 15.

University of Liverpool, School of Clinical Sciences, Liverpool, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc09-0517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732143PMC
September 2009
15 Reads
93 Citations
8.420 Impact Factor

Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera).

J Clin Endocrinol Metab 2007 Jun 26;92(6):2211-4. Epub 2006 Sep 26.

University of California at San Francisco, Valley Research, Fresno, Ca 93720, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2006-0631DOI Listing
June 2007
14 Reads
2 Citations
6.210 Impact Factor

The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.

Diabetes Care 2003 Jun;26(6):1701-5

University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7212, USA.

View Article

Download full-text PDF

Source
June 2003
23 Reads
66 Citations
8.420 Impact Factor